Effects of New Antiepileptic Drugs on Homocysteine in Epileptic Patients: A Systematic Review and Meta-Analysis
Table 1
Characteristics of the studies included in the meta-analysis.
Author
Country
AEDs
Study
AEDs age mean (SD)
AEDs sex (M/F)
Control age mean (SD)
Control sex (M/F)
Duration, (M, Y)
Ramazan 2019
Turkey
Single center
LEV
CS
26.06 (8.61)
13 (−)
28.71 (8.90)
38 (14/24)
7.25 ± 5.47 Y
Meng Sun 2021a
China
Single center
LEV
CS
7.88 (2.85)
35 (19/16)
6.90 (3.82)
35 (18/17)
(3.87 ± 1.02) Y
Meng Sun 2021c
China
Single center
OXC
CS
8.03 (2.86)
34 (18/16)
6.90 (3.82)
35 (17/18)
(3.87 ± 1.02) Y
Belcastro 2010a
Italy
Multicenter
LEV
CS
18–50
32 (−)
40.9 (0.7)
231 (138/93)
>6 M
Belcastro 2010b
Italy
Multicenter
LTG
CS
18–50
33 (−)
40.9 (0.7)
231 (138/93)
>6 M
Belcastro 2010c
Italy
Multicenter
OXC
CS
18–50
45 (−)
40.9 (0.7)
231 (138/93)
>6 M
Belcastro 2010d
Italy
Multicenter
TPM
CS
18–50
41 (−)
40.9 (0.7)
231 (138/93)
>6 M
Algin 2009#
Turkey
Single center
OXC
CS
44.1 (1.6)
11 (5/6)
45 (2.4)
30 (16/14)
1 Y
Algin 2009
Turkey
Single center
OXC
CS
46.3 (1.2)
12 (7/5)
45 (2.4)
30 (16/14)
<1 Y
Emeksiz 2012
Turkey
Single center
OXC
CS
10.8 (3.2)
27 (11/16)
12.1 (3.3)
24 (13/11)
2.7 ± 1.4 Y
Zhu 2021a
China
Single center
LEV
CS
26.26 (8.67)
35 (17/18)
28.58 (10)
65 (31/34)
>6 M
Zhu 2021b
China
Single center
LTG
CS
27.35(6.57)
55 (36/19)
28.58 (10)
65 (31/34)
>6 M
Zhu 2021c
China
Single center
OXC
CS
26.15 (8.84)
71 (35/36)
28.58 (10)
65 (31/34)
>6 M
Mahdavi 2019
Iran
Single center
LEV
CS
30.2 ± 11.7
33 (12/21)
29.9 (11.4)
35 (14/21)
2.24 ± 2.21 Y
Ni 2015
China
Single center
LTG
CS
27.2 (8.4)
30 (15/15)
26.1 (3.9)
30 (15/15)
17 M (6.30)
El-Farahaty 2014a
Egypt
Single center
LEV
CS
11.6 (1.9)
12 (10/2)
13.6 (6.7)
34 (18/16)
2 Y
El-Farahaty 2014b
Egypt
Single center
LTG
CS
17.0 (4.4)
11 (7/4)
13.6 (6.7)
34 (18/16)
2 Y
El-Farahaty 2014d
Egypt
Single center
TPM
CS
13.3 (3.7)
12 (7/5)
13.6 (6.7)
34 (18/16)
2 Y
Chuang 2012
China
Single center
LTG
CS
33.0 (11.6)
26 (8/18)
34.5 (10.5)
60 (30/30)
2 Y
Mahmoud 2021
Egypt
Single center
LEV
CS
4.2 (2.10
53 (29/24)
3.9 (2.3)
53 (34/19)
6 M
Note. LEV, levetiracetam ; LTG, lamotrigine; oxcarbazepine, OXC; topiramate: TPM; month, M; year, Y. aLEV group; bLTG group; cOXC group; dTPM group; CS, cross-sectional study. #In the study, the OXC of duration was more than 1 year. In the study, the OXC of duration was less than 1 year.
